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Following the publication of the above article [1], we noticed
that in Table 1, concerning the data of the study from Garcia-
Vidal the dose of methylprednisolone is not 14.5 mg/day but
45 mg/day.
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Table 1
Recent literature on the role of corticosteroids in severe community-acquired pneumonia
Reference Study design Sample size, Patient selection Corticosteroids Primary endpoints Level of evidence
number (drug/regimen) and 
recommendation
Marik, et al. [21] Single-center RCT 30 Severe CAP Hydrocortisone 10  Mortality, clinical  Weak 
mg/kg versus  course, and serum  recommendation, 
placebo 30 minutes  TNF-α levels moderate-quality 
before antibiotics evidence
Confalonieri, et al. [6] Multicenter RCT 46 Severe CAP Hydrocortisone 200 Mortality, clinical  Strong 
mg +  course, and  recommendation,
hydrocortisone 10  systemic  moderate-quality 
mg/hour, for 7 days  inflammation evidence
versus placebo
Mikami, et al. [20] Open label RCT 31 Moderate and  Prednisolone 40 mg  Mortality and  Weak 
severe CAP qd, for 3 days versus  clinical course recommendation, 
placebo low-quality 
evidence
Garcia-Vidal, et al. [19] Retrospective  308 Severe CAP Methylprednisolone  Mortality Strong 
cohort study 45 mg (or  recommendation, 
equivalent) qd for  low-quality 
11.4 days evidence
CAP, community-acquired pneumonia; qd, quaque die (every day); RCT, randomized controlled trial; TNF-α, tumor necrosis factor-alpha.